(Lung Cancer) Durvalumab Plus Olaparib Combination Achieves 10.5% ORR
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- June 3, 2019
- Reading time: 1 minute
Durvalumab Plus Olaparib in Relapsed Small Cell Lung Cancer: ORR 10.5%
On May 4, 2019, the Journal of Thoracic Oncology published Phase 2 trial results evaluating the efficacy and safety of the durvalumab plus olaparib combination therapy in patients with relapsed small cell lung cancer (SCLC).
Trial Design
This was a single-arm Phase 2 trial administering durvalumab plus olaparib every four weeks to patients with relapsed SCLC, with objective response rate (ORR) as the primary endpoint.
Background: Although immune checkpoint inhibitors demonstrate high anti-cancer efficacy, their effectiveness in SCLC is limited. Combining immune checkpoint inhibitors with PARP inhibitors was hypothesized to improve sensitivity.
Efficacy Results
Among 20 enrolled patients, 19 were evaluable:
- ORR: 10.5%
- Partial response: 1 patient
- Complete response: 1 patient
- Stable disease maintained for ≥6 months
Safety Profile
Most common adverse events confirmed across the majority of patients: anemia, lymphopenia, and leukopenia.
Conclusions
Based on the Phase 2 trial results, this combination therapy did not meet the pre-specified target objective response rate.
Source: Durvalumab in Combination with Olaparib in Patients with Relapsed Small Cell Lung Cancer: Results from a Phase II Study. J Thorac Oncol. 2019 May 4. pii: S1556-0864(19)30361-2. doi: 10.1016/j.jtho.2019.04.026.
Tags: #SmallCellLungCancer #LungCancer
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4